Biotech · Public company · Boston, MA, US
Elicio Therapeutics, Inc.
Ticker ELTX · SEC CIK 0001601485
Track this companyFree. Adds Elicio Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline2
- ELI-002 7PPhase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ELI-002 2PPhase 1 · Minimal Residual DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic CancerPHASE1 · RECRUITING · started Jun 22, 2026ClinicalTrials.gov NCT07671339 · fetched Nov 12, 2026
- A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 14, 2023ClinicalTrials.gov NCT05726864 · fetched Nov 12, 2026
- A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsPHASE1 · COMPLETED · started Oct 4, 2021ClinicalTrials.gov NCT04853017 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026